# VERU — Veru Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** VERU  
**Sources:** 23  
**Published:** 2026-11-01  
**Canonical:** https://app.k3vl4r.com/research/deep-research-veru-veru-inc-catalysts-narrative-risks-10529

---

## Veru Inc. (NASDAQ: VERU) — Point-in-Time Research Snapshot (as of Oct 30–31, 2026)

**Baseline:** As of the Oct 30, 2026 close, VERU traded at ~$2.19 (−1.79% on the day), with a market capitalization of ~$37.3M, a 52-week range of $2.05–$7.33, and a negative trailing P/E. Over the trailing 12 months the stock returned roughly −27.2%, though it is up ~2.3% year-to-date [[9]](https://stockanalysis.com/stocks/veru/forecast/)[[15]](https://www.marketbeat.com/stocks/NASDAQ/VERU/)[[20]](https://stockanalysis.com/stocks/veru/)[[21]](https://finance.yahoo.com/quote/VERU/)[[22]](https://finance.yahoo.com/quote/VERU/). The company is a late-stage, revenue-scarce biopharmaceutical firm (Miami, FL) whose core assets are enobosarm (a SARM) and sabizabulin, plus the historical FC2 female condom business [[2]](https://investingcalendar.com/stock/xnas/veru)[[15]](https://www.marketbeat.com/stocks/NASDAQ/VERU/)[[20]](https://stockanalysis.com/stocks/veru/).

## Recent Catalysts (roughly Aug–Nov 2026)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-veru-veru-inc-catalysts-narrative-risks-10529 (free to sign up)._